Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 11Gastrointestinal 10Thoracic 4Sarcoma 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Ovarian Neoplasms 2

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Enoxaparin × Gynecologic × Clear all
NCT03532139 2025-01-23

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Beth Israel Deaconess Medical Center

Phase 2 Completed
24 enrolled
Gynecologic

Ovarian Neoplasms

NCT00908960 2017-12-19

MicroTEC

Dana-Farber Cancer Institute

Phase 2 Completed
70 enrolled 9 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡